Royalty Report: Cancer, Diagnostic, Medical – Collection: 28893

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 8

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 8

Primary Industries

  • Cancer
  • Diagnostic
  • Medical
  • Disease
  • Drugs
  • Test/Monitoring
  • Antibody
  • Technical Know How
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 28893

License Grant
The Licensor, an unrelated third party, relinquishing all of its exclusive Canadian and limited worldwide marketing rights for DR-70® in exchange for payment and royalties.
License Property
DR-70® test kit is used to assist in the detection of at least 13 different types of cancer, including lung (small and non-small cell); stomach; breast; rectal; colon and liver.
Field of Use
The Licensee is a cancer theranostics company, meaning it is involved in both the detection and treatment of the same disease. We develop, manufacture and offer for sale non-invasive diagnostic kits to hospitals, doctors, clinics, and laboratories, giving them the ability to detect certain types of cancer and H. pylori in their patients.

IPSCIO Record ID: 3603

License Grant
Licensee has resolved litigation concerning allegations relating to a 1998 licence agreement with licensor, an individual, for intellectual property involved in its cancer products. The company retains exclusive rights to the ColorectAlert, LungAlert and the breast cancer test technologies. Under the terms agreed, licensee has entered into an amendment of the existing licensing agreement relating to two existing US and Japanese patents for a technology that detects a carbohydrate marker associated with cancerous and precancerous conditions.
License Property
ColorectAlertâ„¢ is a novel test that identifies people at risk of colorectal cancer at the earliest stages of the disease. The test measures the amount of a cancer-associated carbohydrate, or sugar, in a sample of rectal mucus, which is taken by a physician during a routine digital rectal exam.  ColorectAlertâ„¢ requires a sample of rectal mucus to be taken by a doctor during a digital (gloved finger) rectal exam. This sample can be taken during a routine doctor visit. The sample is smeared onto a proprietary membrane and sent to a laboratory.  At the laboratory, the sample is treated with the enzyme galactose oxidase, then stained with Schiff’s reagent, which produces a color change. The treated sample is read with a color reader (spectrophotometer) to quantify the color change and determine the numeric ColorectAlertâ„¢ value.

LungAlert™ is a novel test that identifies patients at risk of lung cancer at the early stages of the disease. The test detects a cancer-associated sugar in a sample of sputum (phlegm), which is obtained in the doctor’s office by coughing into a cup. Currently, there is no screening test for lung cancer that has proven to save lives.

IPSCIO Record ID: 27476

License Grant
The Licensor granted the Licensee, a long-time partner,  the exclusive rights to sell the products in China provided that the Licensee achieves local regulatory approvals within a 3-year period and does not export from China.
License Property
The Licensor is developing, testing and commercializing its non-invasive lung cancer risk test. The Electro Pulmonary Nodule Scan is a bioconductance measurement method to evaluate the risk of lung cancer in patients with lesions of the lung in well-controlled clinical trials.

The EPN Scan device is designed to provide further information on whether a lung legion may be cancerous after detection by CT Scan.

Field of Use
In February 2014, the Chinese licensee received approval to manufacture, but not market or sell, the device in China as a lung cancer risk stratification device.  On March 15, 2015 the licensee entered clinical trials at two prominent hospitals for the purpose of seeking approval to market and sell the EPN Scanner in China.

IPSCIO Record ID: 256273

License Grant
The German Licensor grants the Swiss Licensee a worldwide, exclusive, right and license, or sublicense, with the right to grant sublicenses, under the Licensed Technology to make, have made, use, offer for sale, sell, and import the Product in the Field in the Territory.

This agreement includes a non-exclusive grant by Licensee to Licensor.

License Property
Licensor is developing a pharmaceutical product comprising a human antibody of IgG-1 subtype binding to EpCAM.

The patents include Novel Method for the Production of anti-human Antigen Receptors and Uses thereof, and, Anti-EpCAM Immunoglobulins.

Decatumumab (MT201) is a recombinant human monoclonal antibody with a binding specificity to epithelial cell adhesion molecule (Ep-CAM). Adecatumumab (MT201) is being evaluated in two European Phase 2 clinical trials, one in patients with prostate cancer, and one in patients with metastatic breast cancer.

Field of Use
The Field means the treatment of human diseases, disorders and conditions.

IPSCIO Record ID: 383585

License Grant
Licensor of Germany grants to the Licensee of Belgium an exclusive worldwide license, with the right to grant sublicenses, under the Licensed IP and Licensor Technology in the Field to develop, have developed, make, have made, use, have used, sell, have sold, import, to have imported, offer for sale and have offered for sale Licensed Products in the Territory.

Licensor grants a non-exclusive worldwide license, with the right to grant sublicenses, under the Licensed IP and Licensor Technology in the Field to develop, have developed, make, have made, use, have used, sell, have sold, import, co have imported, offer for sale and have offered for sale Licensed Products in the Territory. This will secure Licensees non-exclusive access to Licensors Collect technology.

Licensor grants the right to extend the right to use such Licensed Product to their customers of the Licensed Product on which the royalty is paid, label license.

License Property
Licensor owns or controls, on a worldwide basis, the rights, titles and interests in certain patent rights, relating to circulating tumor cells technology.

Licensed Products encompass the components Collect, Select and Detect.

NAT is nucleic acid amplification technology.

Platforms shall mean technologies employed in Licensed Products as well as competitive products based on the same or essentially similar technologies (employing the same scientific or technical principles), used in LIPA, 4•MAT and Luminex systems or certain, identified Real Time PCR technology.

Patents include
Colon cancer Method and Kit for the diagnosis of therapy of colon cancer
Breast cancer Method and Kit for the diagnosis of therapy of breast cancer
Core patent Method and diagnosis kit for selection and/or quantitative detection of cells
Reagency and method for preventing time-dependent RNA -expression in biological cells

Field of Use
The field shall mean circulating tumor cell isolation and detection using existing and future Licensor Technology for breast, colon, lung and upon availability, prostate cancer.

IPSCIO Record ID: 223141

License Grant
The German Licensor hereby grants to Licensee an exclusive license (including the right to grant sublicenses) under the Licensed Patent Rights to conduct research and to develop, make, use, offer for sale, sell and import Licensed Products and to provide Services in the Territory.
License Property
Licensed Patent Rights shall mean (a) those certain patent applications and patents listed hereto; (b) all patents that have issued or in the future issue from such foregoing patent applications, including utility, model and design patents and certificates of invention; (c) all patents that have issued or in the future issue from any patent application that claims priority from, or common priority with, any of the foregoing patent applications, including utility, model and design patents and certificates of invention; and (d) all divisionals, continuations, continuations-in-part, reissues, renewals, extensions or additions to any such foregoing patent
applications and patents.

W003023057 (PCT /EP02/05489) – Method and Diagnosis Kit for Selection and/or for Qualitative and/or Quantitative Detection of Cells

Licensed Products shall mean in-vitro diagnostic assays to isolate, detect, identify, quantify, or test for drug susceptibility of, one or more proteins or nucleic acid sequences as diagnostic indicators for the presence of prostate cancer and/or bladder cancer, for the purpose of research, diagnosis or medical care, the  manufacture, use, sale offer for sale or importation of which would, but for the license herein granted by AdnaGen to Gen-Probe, infringe one or more Valid Claims of the AdnaGen Patent Rights.

Field of Use
This agreement pertains to the medical industry relating to certain technology concerning the qualitative and quantitative detection of cells which may be useful in connection with nucleic acid diagnostic assays. The diagnostic indicators are used for the presence of prostate cancer and/or bladder cancer, for the purpose of research, diagnosis or medical care.

'Group 1 Additional Products' shall mean in-vitro diagnostic assays to isolate, detect, identify or quantify, or test for drug susceptibility of, one or more proteins or nucleic acid sequences as diagnostic indicators for the presence of kidney cancer, cervical cancer, and/or ovarian cancer, for the purpose of research, diagnosis or medical care, the manufacture, use, sale offer for sale or importation of which would, but for the license herein granted by AdnaGen to Gen-Probe, infringe one or more Valid Claims of the Licensed Patent Rights.

'Group 2 Additional Products' shall mean in-vitro diagnostic assays to isolate, detect, identify or quantify, or test for drug susceptibility of, one or more proteins or nucleic acid sequences as diagnostic indicators for the presence of lung cancer, colon cancer, and/or breast cancer, for the purpose of research, diagnosis or medical care, the manufacture, use, sale offer for sale or importation of which would, but for the license herein granted by AdnaGen to Gen-Probe, infringe one or more Valid Claims of the Licensed Patent Rights.

IPSCIO Record ID: 315834

License Grant
For the Licensed Technology, Licensor grants a non-exclusive license under the Licensed Technology to make, have made, use, sell, offer for sale and import Licensed Uses in the Territory in the Field.

For the Research, Licensee shall perform primary testing associated with a validation study of its laboratory -developed test using the Licensed Technology in connection with MD Anderson Cancer Center or an equivalent academic cancer center (with the exception of tissue biopsy) including expression testing, the PSA and send-out of the PCA-3, the Validation Study.  Licensee shall have the right to perform research on remnants after all testing required for the Validation Study is completed, and will be provided reasonable access to the patient data related to the applicable samples.  Licensor shall obtain IRB approval for the study with MD Anderson Cancer Center by February 28, 2009 or, with an equivalent academic institution by June 30, 2009.

For the Purchasing Rights, upon issuance of FDA clearance or approval of an in vitro diagnostic kit using the Licensed Technology (IVD Kit), Licensee shall have the obligation to purchase IVD Kits for reference laboratory use from Licensor’s designated manufacturer or distributor pursuant to a purchasing agreement between Licensee and the applicable manufacturer or distributor, provided however that Licensor shall negotiate to cause such manufacturer or distributor to provide Most Favored Terms to Licensee.

License Property
Licensor has rights in the Licensed Technology covering genomic biomarkers related to prostate cancer.  Licensor is a machine learning company that uses advanced mathematical techniques to analyze large amounts of data to uncover patterns that might otherwise be undetectable. The Company operates primarily in the field of molecular diagnostics where such tools are critical to scientific discovery.

The patents include
Method of Identifying Patterns in Biological Systems and Uses Thereof;
Biomarkers Overexpressed in Prostate Cancer;
Biomarkers Upregulated in Prostate Cancer; and,
Methods for Screening, Predicting and Monitoring Prostate Cancer.

Field of Use
Field shall mean clinical diagnostic applications using biomarkers in urine for differentiating clinically significant prostate cancer from other prostate conditions, including without limitation clinical laboratory testing and clinical trials, but expressly excluding manufacture of in vitro diagnostic kits.

Licensees focus is developing a test for and performing clinical laboratory diagnostic testing using gene biomarkers detected in patient urine samples for differentiating clinically significant prostate cancer from other prostate conditions.

IPSCIO Record ID: 5622

License Grant
The Licensor hereby grants an exclusive license without the right to grant sublicenses in the Territory to the Licensed Intellectual Property to (a) confirm performance of the Colon 101 ELISA Test and (b) use the Colon 101 ELISA Test to offer and provide services within the cDx Field and the rDx Field.

Licensee and its Affiliates shall have the right to use the Trademarks, solely in connection with the use of the Colon 101 ELISA Test.

CDX field means clinical diagnostic testing services performed by a reference laboratory using a test on human samples, the results of which are provided to hospitals, physicians, payers, and/or patients for use in the clinical management of patients.

RDX Field means use in vitro diagnostic testing services in Clinical Trials.

The Licensee shall have the right to use the Trademarks.

License Property
The Licensor has developed a blood test known as the Colon 101 ELISA Test  to detect and quantify the Colon 101 protein in serum.
Field of Use
'CDX Field' means clinical diagnostic testing services performed by a reference laboratory using a test on human samples, the results of which are provided to hospitals, physicians, payers, and/or patients for use in the clinical management of patients.

'RDX Field' means use in in vitro diagnostic testing services in Clinical Trials.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.